Evidence map›Paper›PMID 41367850›Full record

ArticleSaudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society

Monitoring Behçet uveitis.

Hilal Eser-Ozturk, Ilknur Tugal-Tutkun

Abstract read
In one paragraph

Article in Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Behçet disease: A unique systemic vasculitis with a distinct form of ocular involvement.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hilal Eser-OzturkDepartment of Ophthalmology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.
Ilknur Tugal-TutkunEye Protection Foundation, Bayrampasa Eye Hospital, Uveitis Service, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Behçet disease is a systemic vasculitis that can affect various organ systems. Ocular involvement is characterized by recurrent nongranulomatous panuveitis and retinal vasculitis attacks, followed by spontaneous remission periods. Recurrent inflammatory attacks affecting the posterior segment may eventually lead to structural damage and permanent visual loss. The severity of attacks may also be an important factor in visual outcomes. Between attacks, patients may have no clinical signs of inflammatory activity. Therefore, it is crucial to recognize subclinical inflammatory clues in imaging modalities and the structural defects that develop due to previous attacks. Fundus fluorescein angiography (FA) is the gold standard method in monitoring inflammatory activity. Laser flare photometry is a useful noninvasive tool correlating with FA in demonstrating inflammatory activity. Optical coherence tomography (OCT) is the most valuable imaging method in diagnosing and following structural changes. OCT angiography allows visualization of various retinal plexuses separately and evaluation of the retinal vascular structures qualitatively and quantitatively; however, it cannot demonstrate vascular leakage and, therefore, uveitis activity. Monitoring disease activity and structural changes is fundamental in individualizing management, evaluating responses to treatment, and improving long-term outcomes.

Indexed as

Behçet’s disease ocular attack score 24Behçet uveitisfluorescein angiographylaser flare photometry multimodal imagingoptical coherence tomographyoptical coherence tomography angiography

Identifiers

PMID41367850
PMCPMC12685267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.